Zhang Xiao-Long, Pan Shou-Hua, Yan Jia-Jun, Xu Gang
Department of Urology, Shaoxing People's hospital (Shaoxing Hospital, Zhejiang University School of Medicine) Shaoxing, Zhejiang, China.
Medicine (Baltimore). 2018 Jun;97(26):e11213. doi: 10.1097/MD.0000000000011213.
Several studies have been conducted to explore the prognostic value of miR-183 in different types of cancer; however, their results were controversial. Therefore, the present meta-analysis was conducted to comprehensively evaluate the prognostic value of miR-183 expression level in cancer.
A comprehensive literature search was carried out by searching PubMed and EMBASE database between January 1966 and April 2017. Fixed effect and random effect models were used to evaluate the pooled hazard risk (HR) and the relevant 95% confidence intervals (CIs). Subgroup analyses and sensitivity analysis were also carried out.
A total of 12 studies published between 2011 and 2017 were included in the present meta-analysis. The meta-analysis result indicated that there was a significant association between miR-183 expression level and overall survival (HR = 2.642; 95%CI: 2.152-3.245), and there was a significant association between miR-183 expression level and tumor progression (HR = 2.403; 95%CI: 1.267-4.559). In subgroup analysis, we found that high expression level was significantly associated with poor prognosis in most cancers (HR = 2.824, 95%CI: 2.092-3.813); however, low miR-183 level was significantly associated with poor prognosis in melanoma and pancreatic ductal adenocarcinoma (HR = 2.322, 95%CI: 1.337-4.031).
The results of our meta-analysis indicated that the highly expressed miR-183 might predict poor survival of patients with most cancer types, whereas the downregulated miR-183 level might be associated with poor prognosis in patients with melanoma and pancreatic ductal adenocarcinoma.
已有多项研究探讨miR-183在不同类型癌症中的预后价值；然而，其结果存在争议。因此，本荟萃分析旨在全面评估miR-183表达水平在癌症中的预后价值。
通过检索1966年1月至2017年4月期间的PubMed和EMBASE数据库进行全面的文献检索。采用固定效应和随机效应模型评估合并风险比（HR）及相关的95%置信区间（CI）。还进行了亚组分析和敏感性分析。
本荟萃分析共纳入2011年至2017年发表的12项研究。荟萃分析结果表明，miR-183表达水平与总生存期之间存在显著关联（HR = 2.642；95%CI：2.152 - 3.245），且miR-183表达水平与肿瘤进展之间存在显著关联（HR = 2.403；95%CI：1.267 - 4.559）。在亚组分析中，我们发现大多数癌症中高表达水平与预后不良显著相关（HR = 2.824，95%CI：2.092 - 3.813）；然而，黑色素瘤和胰腺导管腺癌中miR-183低水平与预后不良显著相关（HR = 2.322，95%CI：1.337 - 4.031）。
我们的荟萃分析结果表明，高表达的miR-183可能预示大多数癌症类型患者的生存期较差，而miR-183水平下调可能与黑色素瘤和胰腺导管腺癌患者的预后不良有关。
